Full Press Release Details
to Host Investor Webcast Monday, May 17th at 8:30 AM
Eastern Time Regarding Q1 2021 Financials & Business Updates
Webcast registration link appears below
Company plans to file Q1 2021 10-Q on May 17,
San Francisco, CA (May 11, 2021): Jaguar Health, Inc. (NASDAQ:
JAGX) ("Jaguar" or the "Company") today announced that Company management will host a webcast on Monday, May 17,
2021 at 8:30 a.m. Eastern Time to review first-quarter 2021 financials and provide business updates.
Participation Instructions for Webcast
When: Monday, May 17, 2021 at 8:30 AM Eastern Time
Participant Registration & Access Link: Click
About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc.
Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused
on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress,
specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing
proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. Our Mytesi
(crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral
therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.
For more information about Jaguar, please visit https://jaguar.health.
For more information about Napo, visit www.napopharma.com.
Mytesi (crofelemer delayed release tablets) is an antidiarrheal
indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi
is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi .
If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate
therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo
were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available
at Mytesi.com. Crofelemer, the active ingredient in Mytesi , is a botanical (plant-based) drug extracted and purified from
the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting
program for crofelemer to ensure a high degree of quality and ecological integrity.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements." These include statements regarding the Company's expectation that an investor webcast will take place May 17,
2021. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should,"
"expect," "plan," "aim," "anticipate," "could," "intend," "target,"
"project," "contemplate," "believe," "estimate," "predict," "potential"
or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release
are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future
events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties
and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required
by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result
of any new information, future events, changed circumstances or otherwise.
Source: Jaguar Health, Inc.